Biomarkers for precision therapy and prevention of type 2 diabetes

17 September 2021 | Online Meeting

By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.

In the end of the project, the RHAPSODY team shared its achievements with patient and healthcare communities and welcomed all to a half-day symposium on September 17, 2021.

Agenda

Video / Slides
Title
Speaker
Welcome
Bernard Thorens
RHAPSODY academic coordinator, Lausanne
Diabetes care: a clinician`s point of view
Andreas Festa
Eli Lilly, diabetologist
Diabetes care: a patient's perspective
Laying the foundations for targeted prevention and treatments for people living with type2 diabetes and those at risk
Elizabeth Robertson
Diabetes UK,
patient advocate
What does the Innovative Medicines Initiative do to help patients with diabetes?
Claire Varin
RHAPSODY industry coordinator, Servier Paris
The RHAPSODY project:
Biomarkers in type 2 diabetes
Bernard Thorens
RHAPSODY academic coordinator, Lausanne
A new diabetes patient sub-classification: what's next?
Emma Ahlqvist
Lund University Diabetes Centre
A new diabetes patient sub-classification: its application in RHAPSODY
Roderick Slieker
Leiden University Medical Center
Panel discussion
"Why does it matter?"
Moderator: Andreas Festa
Participants:
Claire Varin, Bernard Thorens, Roderick Slieker, Elizabeth Robertson, Steven Kahn (University of Washington, RHAPSODY scientific advisor)
Wrap-up and conclusions
Claire Varin,
Bernard Thorens
Stacks Image 47
Stacks Image 398
Stacks Image 51
Stacks Image 349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.